Mineralys Therapeutics, Inc. Common Stock (MLYS) - Total Liabilities
Based on the latest financial reports, Mineralys Therapeutics, Inc. Common Stock (MLYS) has total liabilities worth $14.72 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Mineralys Therapeutics, Inc. Common Stoc cash conversion from operations to assess how effectively this company generates cash.
Mineralys Therapeutics, Inc. Common Stock - Total Liabilities Trend (2020–2025)
This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check MLYS cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Mineralys Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Mineralys Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TMC the metals company Inc
NASDAQ:TMC
|
USA | $215.07 Million |
|
Ardagh Metal Packaging SA
NYSE:AMBP
|
USA | $5.79 Billion |
|
Fastly, Inc. Class A Common Stock
NYSE:FSLY
|
USA | $569.90 Million |
|
Greatek Electronics Inc
TW:2441
|
Taiwan | NT$3.76 Billion |
|
First Bancorp
NASDAQ:FBNC
|
USA | $11.26 Billion |
|
China Railway Materials Co Ltd
SHE:000927
|
China | CN¥9.64 Billion |
|
EMEIS SA
PA:EMEIS
|
France | €11.57 Billion |
|
Elite Advanced Laser Corp
TW:3450
|
Taiwan | NT$5.44 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Mineralys Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Mineralys Therapeutics, Inc. Common Stoc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 44.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mineralys Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mineralys Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual total liabilities of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $15.11 Million | +3.19% |
| 2024-12-31 | $14.65 Million | +39.73% |
| 2023-12-31 | $10.48 Million | -93.71% |
| 2022-12-31 | $166.71 Million | +389.61% |
| 2021-12-31 | $34.05 Million | +569.88% |
| 2020-12-31 | $5.08 Million | -- |
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, an… Read more